Seth Lerner
MD
Beth and Dave Swalm Chair in Urologic Oncology
👥Biography 个人简介
Seth Lerner at Baylor is a urologic oncologist who has contributed to surgical management of bladder cancer and to clinical development of intravesical therapies for BCG-unresponsive non-muscle invasive bladder cancer. He led the pivotal trial of nadofaragene firadenovec (an adenoviral vector expressing interferon-alpha2b) that led to its approval for BCG-unresponsive NMIBC — a new treatment option for a historically difficult-to-treat patient population.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Seth Lerner 的研究动态
Follow Seth Lerner's research updates
留下邮箱，当我们发布与 Seth Lerner（Baylor College of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment